Roflumilast Tablets

Therapeutic Indication

Severe COPD with chronic bronchitis

Reduces risk of exacerbations

Roflumilast

Tablet

Roflumilast is a selective phosphodiesterase-4 (PDE-4) inhibitor that reduces inflammation in the lungs. It is used as maintenance therapy in severe COPD associated with chronic bronchitis to lower the risk of exacerbations.

Speciality	Pulmonology \| Internal Medicine
Tags	PDE-4 Inhibitor \| COPD Management
Strength	500 mcg
Packing Size	10 Tablets

Check all Tablets Range

Click to know More

Mechanism

Roflumilast inhibits PDE-4, leading to increased intracellular cAMP levels, which reduces inflammation in the lungs and improves respiratory function.

Pharmacokinetics

Absorption: Rapid oral absorption
Metabolism: Hepatic (CYP3A4, CYP1A2)
Elimination: Renal and fecal excretion
Half-life: 17 hours

Side Effects

Diarrhea
Weight loss
Headache
Insomnia
Rare: Psychiatric symptoms (depression, anxiety)

Contraindication

Moderate to severe hepatic impairment
Hypersensitivity to Roflumilast

Interaction

Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine)
CYP3A4 inhibitors may increase plasma levels

Warning and Precautions

Monitor renal and hepatic function regularly
Monitor weight regularly
Use with caution in patients with depression
Not recommended in severe liver disease

Dosage

As directed by the Physician.